Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

by

in

Partnership will investigate the underlying disease mechanisms of multiple sclerosis (MS) with the potential of finding new relevant drug targets

MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with Cardiff University Centre for Neuropsychiatric Genetics and Genomics, a renowned institution at the forefront of biomedical research. This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).

MS is a neuroinflammatory disorder that affects the central nervous system, giving rise to a range of physical and neuropsychological challenges. Worldwide, more than 2.8 million people are living with …

Full story available on Benzinga.com